RICHMOND, VA., October 24 /CNW/ - Insmed Inc. (Nasdaq: INSM) today
announced that it will release its 2007 third quarter results after market
closes on Thursday, November 8, 2007.
Management will host an investment community conference call beginning at
4:30 p.m. (ET) on Thursday, November 8, 2007 to discuss the financial results,
provide a business update and answer questions.
Individuals interested in listening to the live conference call may do so
by dialing 877-407-0778 toll free within the U.S. and Canada, or 201-689-8565
for international callers.
A telephone replay will be available approximately two hours after the
call for two weeks by dialing 877-660-6853 from the U.S., or 201-612-7415 for
international callers. The account # is 286 and conference id # 259108.
Individuals interested in listening to the conference call via the
Internet may do so by visiting www.insmed.com. A replay will be available on
the Company's Web site for 90 days.
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the development of drug
candidates for the treatment of metabolic diseases and endocrine disorders
with unmet medical needs. For more information, please visit www.insmed.com.
Forward Looking Statements
This release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of 1934. Investors
are cautioned that such statements in this release, including statements
relating to planned clinical study design, regulatory and business strategies,
plans and objectives of management and growth opportunities for existing or
proposed products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ materially from
those anticipated by the forward-looking statements. The risks and
uncertainties include, without limitation, risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured, we may
lack financial resources to complete development of product candidates, the
FDA may interpret the results of studies differently than us, competing
products may be more successful, demand for new pharmaceutical products may
decrease, the biopharmaceutical industry may experience negative market
trends, our entrance into the follow on biologics market may be unsuccessful,
our common stock could be delisted from the Nasdaq Global Market and other
risks and challenges detailed in our filings with the U.S. Securities and
Exchange Commission, including our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2007. Readers are cautioned not to place undue reliance
on any forward-looking statements which speak only as of the date of this
release. We undertake no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
For further information:
For further information: Investor Relations International Haris Tajyar,